CN Patent

CN112494500B — 瑞德西韦在制备治疗抗肿瘤药物心脏毒性药物中的应用

Assigned to Beijing Jianmu Technology Co Ltd · Expires 2022-01-11 · 4y expired

What this patent protects

本发明公开了瑞德西韦(Remdesivir)在制备治疗抗肿瘤药物心脏毒性药物中的应用。本发明证实了瑞德西韦作为抑制肿瘤药物心脏毒性药物的重大潜力，首次公开了瑞德西韦对抗肿瘤药物导致的心脏毒性的良好疗效，为抗肿瘤药物的心脏毒性治疗提供了有效的新型潜在备选药物，扩展了瑞德西韦的适应证，极大的提高了瑞德西韦的应用潜力及市场前景。

USPTO Abstract

本发明公开了瑞德西韦(Remdesivir)在制备治疗抗肿瘤药物心脏毒性药物中的应用。本发明证实了瑞德西韦作为抑制肿瘤药物心脏毒性药物的重大潜力，首次公开了瑞德西韦对抗肿瘤药物导致的心脏毒性的良好疗效，为抗肿瘤药物的心脏毒性治疗提供了有效的新型潜在备选药物，扩展了瑞德西韦的适应证，极大的提高了瑞德西韦的应用潜力及市场前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN112494500B
Jurisdiction
CN
Classification
—
Expires
2022-01-11
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Jianmu Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.